Human Osteoprotegerin ELISA Kit is a sandwich ELISA designed to quantify Human Osteoprotegerin with a sensitivity of 1 pg/mL.
- Colorimetric sandwich ELISA - 450 nm readout - works on any plate reader
- Wide dynamic range - quantifies 1.23 - 900 pg/mL
- Cited in over 10 publications
Application | Reactivity | Dilution info | Notes |
---|---|---|---|
Application sELISA | Reactivity Reacts | Dilution info - | Notes - |
Select an associated product type
Acts as a decoy receptor for TNFSF11/RANKL and thereby neutralizes its function in osteoclastogenesis. Inhibits the activation of osteoclasts and promotes osteoclast apoptosis in vitro. Bone homeostasis seems to depend on the local ratio between TNFSF11 and TNFRSF11B. May also play a role in preventing arterial calcification. May act as decoy receptor for TNFSF10/TRAIL and protect against apoptosis. TNFSF10/TRAIL binding blocks the inhibition of osteoclastogenesis.
OCIF, OPG, TNFRSF11B, Tumor necrosis factor receptor superfamily member 11B, Osteoclastogenesis inhibitory factor, Osteoprotegerin
Human Osteoprotegerin ELISA Kit is a sandwich ELISA designed to quantify Human Osteoprotegerin with a sensitivity of 1 pg/mL.
- Colorimetric sandwich ELISA - 450 nm readout - works on any plate reader
- Wide dynamic range - quantifies 1.23 - 900 pg/mL
- Cited in over 10 publications
Sample type | Average % | Range |
---|---|---|
Sample type Cell culture supernatant | Average % = 99.75 | Range 89 - 108 % |
Sample type Serum | Average % = 99.85 | Range 89 - 108 % |
Sample type Plasma | Average % = 102.45 | Range 90 - 109 % |
Abcam's Osteoprotegerin Human ELISA (Enzyme-Linked Immunosorbent Assay) kit is an in vitro enzyme-linked immunosorbent assay for the quantitative measurement of Human Osteoprotegerin in serum, plasma, and cell culture supernatants.
This assay employs an antibody specific for Human Osteoprotegerin coated on a 96-well plate. Standards and samples are pipetted into the wells and Osteoprotegerin present in a sample is bound to the wells by the immobilized antibody. The wells are washed and biotinylated anti-Human Osteoprotegerin antibody is added. After washing away unbound biotinylated antibody, HRP-conjugated streptavidin is pipetted to the wells. The wells are again washed, a TMB substrate solution is added to the wells and color develops in proportion to the amount of Osteoprotegerin bound. The Stop Solution changes the color from blue to yellow, and the intensity of the color is measured at 450 nm.
Get results in 90 minutes with Human Osteoprotegerin ELISA Kit (Human Osteoprotegerin ELISA Kit ab189580) from our SimpleStep ELISA® range.
Produced using a non-baculovirus expression system.
Optimization may be required with urine samples.
We recommend preparing serum-free or low-serum medium samples, as serum tends to contain cytokines which may produce significant background signals. If it is necessary to test serum-containing medium, we recommend also running an uncultured media blank to assess baseline signals. This baseline can then be subtracted from the cultured media sample data.
Osteoprotegerin (OPG) also known as osteoclastogenesis inhibitory factor is a glycoprotein with a mass of approximately 60 kDa. It acts as a soluble decoy receptor for receptor activator of nuclear factor kappa-Β ligand (RANKL) and is encoded by the TNFRSF11B gene. OPG is mainly expressed in osteoblasts fibroblasts and endothelial cells. Its expression can be found in diverse tissues throughout the body including the liver and lungs.
OPG inhibits the differentiation and activation of osteoclasts by binding to RANKL preventing its interaction with the receptor RANK on the surface of osteoclast progenitor cells. As part of a non-classical signaling pathway OPG plays a significant role in the regulation of bone remodeling and maintenance by controlling bone resorption. This activity preserves bone density and structure by limiting excessive osteoclastic activity.
OPG operates within the RANK/RANKL/OPG signaling axis which is important for bone metabolism. It counteracts the bone-resorption pathway driven by the RANKL-RANK interaction inhibiting osteoclastogenesis. This axis involves interactions with other proteins such as RANK RANKL and TRAIL where TRAIL’s involvement hints towards a broader immune regulation role for OPG.
OPG has a significant association with conditions such as osteoporosis and vascular calcification. In osteoporosis an imbalance in the RANKL/OPG ratio can lead to excessive bone loss due to increased osteoclast activity. In vascular calcification OPG appears to play a protective role likely linked with regulatory mechanisms involving RANKL and TRAIL. Understanding these interactions opens potential therapeutic avenues particularly in managing bone-related and cardiovascular conditions.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
Osteoprotegerin measured in cell lysates showing quantity (pg) per mg of tested sample
Representative Standard Curve using ab100617.
Representative Standard Curve using ab100617.
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com